Scholarlink

<p>Although novel drugs have recently been introduced in the clinic, the survival rates of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are not yet satisfactory; thus, developing novel strategies with different modes of action is urgently needed. Immunotherapy against AML/MDS is less feasible than that for B-cell malignancies because commonly and uniformly expressed cell-surface targets are lacking, and HLA constraints further limit patient eligibility. Careful patient selection based on high and homogeneous target antigen expression in AML/MDS cells may serve as a biomarker. In this review, we first describe T-cell receptor (TCR) T-cell therapy development processes, then review recent clinical trials and future perspectives.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Current status and challenges of TCR-T cell therapy for AML/MDS

  • 期刊论文

  • 发表日期：

    2026年6月18日

查看全文
  • Yoshiki Akatsuka

摘要

Although novel drugs have recently been introduced in the clinic, the survival rates of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are not yet satisfactory; thus, developing novel strategies with different modes of action is urgently needed. Immunotherapy against AML/MDS is less feasible than that for B-cell malignancies because commonly and uniformly expressed cell-surface targets are lacking, and HLA constraints further limit patient eligibility. Careful patient selection based on high and homogeneous target antigen expression in AML/MDS cells may serve as a biomarker. In this review, we first describe T-cell receptor (TCR) T-cell therapy development processes, then review recent clinical trials and future perspectives.